MedTrace Logo

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

NCT04343768 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-05-05

No results posted yet for this study

Summary

The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the three arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

Conditions

Interventions

DRUG

Hydroxychloroquine

This Drug will be used in all arms.

DRUG

Lopinavir / Ritonavir

This Drug will be used in all arms.

DRUG

Interferon Beta-1A

This drug will be only used in Arm 1.

DRUG

Interferon Beta-1B

This drug will be only used in Arm 2.

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Ilad Alavi Darazam, MD · Shahid Beheshti University of Medical Sciences

  • Shervin Shokouhi, MD · Shahid Beheshti University of Medical Sciences

  • Minoosh Shabani, MD · Shahid Beheshti University of Medical Sciences

  • Mohammadreza Haji Esmaelie, MD · Shahid Beheshti University of Medical Sciences

  • Seyed Sina Naghibi Irvani, MD, MPH, MBA · Shahid Beheshti University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2020-04-27
Completion
2020-04-27

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343768 on ClinicalTrials.gov